PURPOSE: Angiogenesis plays a crucial role in metastatic progression of soft tissue sarcomas (STS). Endothelial cells are the primary target of metronomic chemotherapy. We report the safety and the efficacy of metronomic chemotherapy in metastatic STS patients. METHODS: The medical charts of 26 metastatic STS patients treated at Institut Bergonie (Bordeaux, France) with metronomic etoposide (100 mg/day orally for 21 consecutive days, repeated every 4 weeks) were reviewed by two independent investigators. RESULTS: Median age was 49. All but three patients received prior treatment with doxorubicin and/or ifosfamide. One patient (4%) had partial response and 11 patients (42%) had stable disease for more than 24 weeks. The 6-month and the 1-year progression-free survival rates were 42% [95% CI: 23; 61] and 23% [95% CI: 7; 39], respectively. The 6-month and the 1-year overall survival rates were 69% [95% CI: 51; 87] and 31% [95% CI: 13; 49], respectively. Two patients experienced grade 4 febrile neutropenia and one of them died of sepsis. CONCLUSION: In this series, metronomic etoposide was associated with significant clinical activity in STS. Further prospective investigations are necessary to identify those patients who are more likely to benefit from this strategy.
PURPOSE: Angiogenesis plays a crucial role in metastatic progression of soft tissue sarcomas (STS). Endothelial cells are the primary target of metronomic chemotherapy. We report the safety and the efficacy of metronomic chemotherapy in metastatic STS patients. METHODS: The medical charts of 26 metastatic STS patients treated at Institut Bergonie (Bordeaux, France) with metronomicetoposide (100 mg/day orally for 21 consecutive days, repeated every 4 weeks) were reviewed by two independent investigators. RESULTS: Median age was 49. All but three patients received prior treatment with doxorubicin and/or ifosfamide. One patient (4%) had partial response and 11 patients (42%) had stable disease for more than 24 weeks. The 6-month and the 1-year progression-free survival rates were 42% [95% CI: 23; 61] and 23% [95% CI: 7; 39], respectively. The 6-month and the 1-year overall survival rates were 69% [95% CI: 51; 87] and 31% [95% CI: 13; 49], respectively. Two patients experienced grade 4 febrile neutropenia and one of them died of sepsis. CONCLUSION: In this series, metronomicetoposide was associated with significant clinical activity in STS. Further prospective investigations are necessary to identify those patients who are more likely to benefit from this strategy.
Authors: Guido Bocci; Anna Fioravanti; Paola Orlandi; Teresa Di Desidero; Gianfranco Natale; Giovanni Fanelli; Paolo Viacava; Antonio Giuseppe Naccarato; Giulio Francia; Romano Danesi Journal: Neoplasia Date: 2012-09 Impact factor: 5.715
Authors: Audrey Perret; Julien Dômont; Ali N Chamseddine; Sarah N Dumont; Benjamin Verret; Sylvain Briand; Charles Court; Thierry Lazure; Julien Adam; Carine Ngo; Caroline Even; Antonin Levy; Arnaud Bayle; Francesca Lucibello; Leila Haddag-Miliani; Matthieu Faron; Charles Honoré; Axel Le Cesne; Olivier Mir Journal: Cancer Med Date: 2020-11-25 Impact factor: 4.452